Modeling the clinical phenotype of BTK inhibition in the mature murine immune system

Journal of Immunology

Volumn 193, Issue 1, 2014, Pages 185-197

  Benson, Micah J ^a   Rodriguez, Varenka ^a   Von Schack, David ^a   Keegan, Sean ^a   Cook, Tim A ^a   Edmonds, Jason ^a   Benoit, Stephen ^a   Seth, Nilufer ^a   Du, Sarah ^a   Messing, Dean ^a   Nickerson Nutter, Cheryl L ^a   Dunussi Joannopoulos, Kyri ^a   Rankin, Andrew L ^a   Ruzek, Melanie ^a   Schnute, Mark E ^a   Douhan III, John ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 3 [4 (4 CHLOROPHENOXY)PHENYL] 1 (1 CYANOPIPERIDIN 3 YL) 1H PYRAZOLE 4 CARBOXAMIDE; B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; IMMUNOGLOBULIN M; PF 303; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; BTK GENE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; B-LYMPHOCYTE SUBSETS; CELL SURVIVAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN M; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED CBA; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84903595313     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302570     Document Type: Article

References (50)

1. Niiro, H., and E. A. Clark. 2002. Regulation of B-cell fate by antigen-receptor signals. Nat. Rev. Immunol. 2: 945-956.
2. Benson, M. J., L. D. Erickson, M. W. Gleeson, and R. J. Noelle. 2007. Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr. Opin. Immunol. 19: 275-280.
3. Mohamed, A. J., L. Yu, C. M. Bäckesjö, L. Vargas, R. Faryal, A. Aints, B. Christensson, A. Berglö f, M. Vihinen, B. F. Nore, and C. I. Smith. 2009. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 228: 58-73.
4. Khan, W. N., F. W. Alt, R. M. Gerstein, B. A. Malynn, I. Larsson, G. Rathbun, L. Davidson, S. Müller, A. B. Kantor, L. A. Herzenberg, et al. 1995. Defective B cell development and function in Btk-deficient mice. Immunity 3: 283-299.
5. Kerner, J. D., M. W. Appleby, R. N. Mohr, S. Chien, D. J. Rawlings, C. R. Maliszewski, O. N. Witte, and R. M. Perlmutter. 1995. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 3: 301-312.
6. Khan, W. N. 2009. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J. Immunol. 183: 3561-3567.
7. Satterthwaite, A. B., and O. N. Witte. 2000. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol. Rev. 175: 120-127.
8. Vetrie, D., I. Vorechovský, P. Sideras, J. Holland, A. Davies, F. Flinter, L. Hammarström, C. Kinnon, R. Levinsky, M. Bobrow, et al. 1993. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361: 226-233.
9. Tsukada, S., D. C. Saffran, D. J. Rawlings, O. Parolini, R. C. Allen, I. Klisak, R. S. Sparkes, H. Kubagawa, T. Mohandas, S. Quan, et al. 1993. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72: 279-290.
10. Thomas, J. D., P. Sideras, C. I. Smith, I. Vorechovský, V. Chapman, and W. E. Paul. 1993. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261: 355-358.
11. Rawlings, D. J., D. C. Saffran, S. Tsukada, D. A. Largaespada, J. C. Grimaldi, L. Cohen, R. N. Mohr, J. F. Bazan, M. Howard, N. G. Copeland, et al. 1993. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261: 358-361.
12. Ng, Y. S., H. Wardemann, J. Chelnis, C. Cunningham-Rundles, and E. Meffre. 2004. Bruton's tyrosine kinase is essential for human B cell tolerance. J. Exp. Med. 200: 927-934.
13. Hayakawa, K., R. R. Hardy, and L. A. Herzenberg. 1986. Peritoneal Ly-1 B cells: genetic control, autoantibody production, increased lambda light chain expression. Eur. J. Immunol. 16: 450-456.
14. Conley, M. E., O. Parolini, J. Rohrer, and D. Campana. 1994. X-linked agammaglobulinemia: new approaches to old questions based on the identification of the defective gene. Immunol. Rev. 138: 5-21.
15. Cancro, M. P., A. P. Sah, S. L. Levy, D. M. Allman, M. R. Schmidt, and R. T. Woodland. 2001. xid mice reveal the interplay of homeostasis and Bruton's tyrosine kinase-mediated selection at multiple stages of B cell development. Int. Immunol. 13: 1501-1514.
16. Scher, I. 1982. The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunity. Adv. Immunol. 33: 1-71.
17. Hardy, R. R., K. Hayakawa, D. R. Parks, L. A. Herzenberg, and L. A. Herzenberg. 1984. Murine B cell differentiation lineages. J. Exp. Med. 159: 1169-1188.
18. Honigberg, L. A., A. M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, S. Li, Z. Pan, D. H. Thamm, R. A. Miller, and J. J. Buggy. 2010. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 107: 13075-13080.
19. Chang, B. Y., M. M. Huang, M. Francesco, J. Chen, J. Sokolove, P. Magadala, W. H. Robinson, and J. J. Buggy. 2011. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13: R115.
20. Ponader, S., S. S. Chen, J. J. Buggy, K. Balakrishnan, V. Gandhi, W. G. Wierda, M. J. Keating, S. O'Brien, N. Chiorazzi, and J. A. Burger. 2012. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119: 1182-1189.
21. Kim, K. H., A. Maderna, M. E. Schnute, M. Hegen, S. Mohan, J. Miyashiro, L. Lin, E. Li, S. Keegan, J. Lussier, et al. 2011. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 21: 6258-6263.
22. Hutcheson, J., K. Vanarsa, A. Bashmakov, S. Grewal, D. Sajitharan, B. Y. Chang, J. J. Buggy, X. J. Zhou, Y. Du, A. B. Satterthwaite, and C. Mohan. 2012. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res. Ther. 14: R243.
23. Xu, D., Y. Kim, J. Postelnek, M. D. Vu, D. Q. Hu, C. Liao, M. Bradshaw, J. Hsu, J. Zhang, A. Pashine, et al. 2012. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 341: 90-103.
24. Rankin, A. L., N. Seth, S. Keegan, T. Andreyeva, T. A. Cook, J. Edmonds, N. Mathialagan, M. J. Benson, J. Syed, Y. Zhan, et al. 2013. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J. Immunol. 191: 4540-4550.
25. Byrd, J. C., R. R. Furman, S. E. Coutre, I. W. Flinn, J. A. Burger, K. A. Blum, B. Grant, J. P. Sharman, M. Coleman, W. G. Wierda, et al. 2013. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369: 32-42.
26. Wang, M. L., S. Rule, P. Martin, A. Goy, R. Auer, B. S. Kahl, W. Jurczak, R. H. Advani, J. E. Romaguera, M. E. Williams, et al. 2013. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369: 507-516.
27. Ridderstad, A., G. J. Nossal, and D. M. Tarlinton. 1996. The xid mutation diminishes memory B cell generation but does not affect somatic hypermutation and selection. J. Immunol. 157: 3357-3365.
28. Ridderstad, A., and D. M. Tarlinton. 1997. B cell memory in xid mice is longlived despite reduced memory B cell frequency. Scand. J. Immunol. 45: 655-659.
29. Amsbaugh, D. F., C. T. Hansen, B. Prescott, P. W. Stashak, D. R. Barthold, and P. J. Baker. 1972. Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J. Exp. Med. 136: 931-949.
30. Ochs, H. D., and C. I. Smith. 1996. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore) 75: 287-299.
31. Conley, M. E. 1985. B cells in patients with X-linked agammaglobulinemia. J. Immunol. 134: 3070-3074.
32. Campana, D., J. Farrant, N. Inamdar, A. D. Webster, and G. Janossy. 1990. Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. J. Immunol. 145: 1675-1680.
33. Muul, L. M., I. Scher, J. J. Mond, and F. D. Finkelman. 1983. Polyclonal activation of the murine immune system by an antibody to IgD. IV. In vivo activation of B lymphocytes from immune defective CBA/N mice. J. Immunol. 131: 2226-2231.
34. Scher, I., A. Ahmed, D. M. Strong, A. D. Steinberg, and W. E. Paul. 1975. Xlinked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J. Exp. Med. 141: 788-803.
35. Khan, W. N., P. Sideras, F. S. Rosen, and F. W. Alt. 1995. The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Ann. N. Y. Acad. Sci. 764: 27-38.
36. Shih, T. A., M. Roederer, and M. C. Nussenzweig. 2002. Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 3: 399-406.
37. Glynne, R., G. Ghandour, J. Rayner, D. H. Mack, and C. C. Goodnow. 2000. Blymphocyte quiescence, tolerance and activation as viewed by global gene expression profiling on microarrays. Immunol. Rev. 176: 216-246.
38. Glynne, R., S. Akkaraju, J. I. Healy, J. Rayner, C. C. Goodnow, and D. H. Mack. 2000. How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis. Nature 403: 672-676.
39. Allman, D., R. C. Lindsley, W. DeMuth, K. Rudd, S. A. Shinton, and R. R. Hardy. 2001. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J. Immunol. 167: 6834-6840.
40. Benson M. J., R. Elgueta, W. Schpero, M. Molloy, W. Zhang, E. Usherwood, and R. J. Noelle. 2009. Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J. Exp. Med. 206: 2013-2025.
41. Kraus, M., M. B. Alimzhanov, N. Rajewsky, and K. Rajewsky. 2004. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117: 787-800.
42. Srinivasan, L., Y. Sasaki, D. P. Calado, B. Zhang, J. H. Paik, R. A. DePinho, J. L. Kutok, J. F. Kearney, K. L. Otipoby, and K. Rajewsky. 2009. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139: 573-586.
43. Lam, K. P., R. Kühn, and K. Rajewsky. 1997. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90: 1073-1083.
44. Schweighoffer, E., L. Vanes, J. Nys, D. Cantrell, S. McCleary, N. Smithers, and V. L. Tybulewicz. 2013. The BAFF receptor transduces survival signals by coopting the B cell receptor signaling pathway. Immunity 38: 475-488.
45. de Gorter, D. J., E. A. Beuling, R. Kersseboom, S. Middendorp, J. M. van Gils, R. W. Hendriks, S. T. Pals, and M. Spaargaren. 2007. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26: 93-104.
46. Chang, B. Y., M. Francesco, M. F. De Rooij, P. Magadala, S. M. Steggerda, M. M. Huang, A. Kuil, S. E. Herman, S. Chang, S. T. Pals, et al. 2013. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122: 2412-2424.
47. Merrell, K. T., R. J. Benschop, S. B. Gauld, K. Aviszus, D. Decote-Ricardo, L. J. Wysocki, and J. C. Cambier. 2006. Identification of anergic B cells within a wild-type repertoire. Immunity 25: 953-962.
48. Ellmeier, W., S. Jung, M. J. Sunshine, F. Hatam, Y. Xu, D. Baltimore, H. Mano, and D. R. Littman. 2000. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J. Exp. Med. 192: 1611-1624.
49. Benson, M. J., S. R. Dillon, E. Castigli, R. S. Geha, S. Xu, K. P. Lam, and R. J. Noelle. 2008. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180: 3655-3659.
50. Scholz, J. L., J. E. Crowley, M. M. Tomayko, N. Steinel, P. J. O'Neill, W. J. Quinn, III, R. Goenka, J. P. Miller, Y. H. Cho, V. Long, et al. 2008. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl. Acad. Sci. USA 105: 15517-15522.